2 Top Gene-Editing Stocks to Buy Right Now
Gene-editing technology allows for the manipulation of the basic building blocks of life, so to speak. It grants scientists the ability to add, remove, or modify the genetic material of an organism, which can affect how said organism functions. Treatments based on this technology seek to replace the defective genes responsible for a medical condition with healthy versions. This technique can lead to the development of treatments or cures for diseases that are otherwise extremely difficult, if not impossible, to treat.
Developing a treatment for an illness with a serious unmet need often turns out to be highly lucrative for a biotech company. In other words, it might be a good idea for investors to look through the current biotech leaders in the field of gene editing and figure out which of them could be winners in the long run. Among the many biotech companies that focus on gene editing, two of the most promising are CRISPR Therapeutics (NASDAQ: CRSP) and bluebird bio (NASDAQ: BLUE). Here's why.
CRISPR Therapeutics made a lot of noise last year when it announced positive results from a phase 1/2 trial for its most promising pipeline candidate, CTX001. This product is being developed as a potential treatment for two blood disorders called sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
Source Fool.com
